Abstract
Recently, significant progress has been made towards understanding the pathogenesis of cancer from the molecular standpoint. To this end, a growing number of approaches are being exploited for the identification and validation of new therapeutic targets suitable for potent and specific intervention. The type 1 insulin-like growth factor receptor (IGF-1R) system has recently become the focus of major attention in the arena of cancer research. The involvement of the receptor and its downstream signaling cascades in the carcinogenesis process makes this system an excellent target for potential cancer therapy. Indeed, advances in the understanding of the molecular mechanisms behind IGF-1R activation have led to the discovery of agents designed selectively for targeting IGF-1R. The potential application of these inhibitors is currently under intense clinical investigation. This review describes the biology of IGF-1R particularly from a cancer perspective. The attempts to develop effective IGF-1R antagonists are discussed comprehensively with special emphasis on antibodies and small tyrosine kinase inhibitors.
Keywords: Tumor growth, apoptosis, IGF-1R, RTK, antibody, TKI, cancer therapy
Combinatorial Chemistry & High Throughput Screening
Title: Targeted Therapy of the Insulin-Like Growth Factor-1 Receptor in Cancer
Volume: 11 Issue: 1
Author(s): Keren Paz and Yaron R. Hadari
Affiliation:
Keywords: Tumor growth, apoptosis, IGF-1R, RTK, antibody, TKI, cancer therapy
Abstract: Recently, significant progress has been made towards understanding the pathogenesis of cancer from the molecular standpoint. To this end, a growing number of approaches are being exploited for the identification and validation of new therapeutic targets suitable for potent and specific intervention. The type 1 insulin-like growth factor receptor (IGF-1R) system has recently become the focus of major attention in the arena of cancer research. The involvement of the receptor and its downstream signaling cascades in the carcinogenesis process makes this system an excellent target for potential cancer therapy. Indeed, advances in the understanding of the molecular mechanisms behind IGF-1R activation have led to the discovery of agents designed selectively for targeting IGF-1R. The potential application of these inhibitors is currently under intense clinical investigation. This review describes the biology of IGF-1R particularly from a cancer perspective. The attempts to develop effective IGF-1R antagonists are discussed comprehensively with special emphasis on antibodies and small tyrosine kinase inhibitors.
Export Options
About this article
Cite this article as:
Paz Keren and Hadari R. Yaron, Targeted Therapy of the Insulin-Like Growth Factor-1 Receptor in Cancer, Combinatorial Chemistry & High Throughput Screening 2008; 11 (1) . https://dx.doi.org/10.2174/138620708783398313
DOI https://dx.doi.org/10.2174/138620708783398313 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sch-66336 (Sarasar®) and Other Benzocycloheptapyridyl Farnesyl Protein Transferase Inhibitors: Discovery, Biology and Clinical Observations
Current Topics in Medicinal Chemistry Chimeric Antigen Receptor T Cells: Self-Replicating Drugs for Cancer
Current Drug Targets Pleural Fluid Analysis for Evaluating Pleural Effusions
Current Respiratory Medicine Reviews How Inhaled Asbestos Causes Scarring and Cancer
Current Respiratory Medicine Reviews Will Antiangiogenic Agents be a Future for Mesothelioma Therapy?
Current Medicinal Chemistry Notch Signaling: A Potential Therapeutic Target in Prostate Cancer
Current Cancer Drug Targets Antifolates - Past, Present and Future
Current Medicinal Chemistry - Anti-Cancer Agents The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design Towards Human on a Chip: Recent Progress and Future Perspective
Micro and Nanosystems Current Targeting Strategies for Adenovirus Vectors in Cancer Gene Therapy
Current Cancer Drug Targets New Generation of Oncolytic Herpes Virus
Current Cancer Therapy Reviews Carbon Nanotubes in the Treatment of Skin Cancers: Safety and Toxic ological Aspects
Pharmaceutical Nanotechnology MicroRNA-dependent Regulation of Telomere Maintenance Mechanisms: A Field as Much Unexplored as Potentially Promising
Current Pharmaceutical Design Melatonin Regulates Angiogenic Factors under Hypoxia in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem Cells Switch on Tumor Neovascularization
Current Molecular Medicine 86Y Based PET Radiopharmaceuticals: Radiochemistry and Biological Applications
Medicinal Chemistry Gefitinib Targets EGFR Dimerization and ERK1/2 Phosphorylation to Inhibit Pleural Mesothelioma Cell Proliferation
Current Cancer Drug Targets MDA-7/IL-24-Based Cancer Gene Therapy: Translation from the Laboratory to the Clinic
Current Gene Therapy Recent Achievements in the Chemistry of 1,2-Diazines
Current Organic Chemistry IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets